EPHA2 and hepatocellular carcinoma: Collectively, the application of the small molecule inhibitor ALW-II-41-27 (ALW) demonstrated significant reduction in the phosphorylation of EPHA2 and its downstream effectors in HCC cells, impairing their growth in vitro.